Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
Paris, France, March 28th 2018 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Medicines Agency (EMA), the European regulatory authority, has validated the filing of a new application for an additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
The filing is based on the results of the global placebo-controlled phase 3 CELESTIAL trial which met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant improvement and clinically meaningful improvement in median OS compared with placebo in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib.
Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen, said:
“This milestone is an important step forward for the cabozantinib ongoing development program
across solid tumors, with the potential, if approved, to provide patients with advanced HCC – which is still an unmet medical need – with a new oral systemic treatment.”
Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
Paris, France, March 28th 2018 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Medicines Agency (EMA), the European regulatory authority, has validated the filing of a new application for an additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
The filing is based on the results of the global placebo-controlled phase 3 CELESTIAL trial which met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant improvement and clinically meaningful improvement in median OS compared with placebo in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib.
Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen, said:
“This milestone is an important step forward for the cabozantinib ongoing development program
across solid tumors, with the potential, if approved, to provide patients with advanced HCC – which is still an unmet medical need – with a new oral systemic treatment.”
Related Press Releases
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary...
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Ipsen publishes its 2024 Universal Registration Document
Ipsen announces issuance of €500 million inaugural Rated Public Bond
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025